$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Oncology
Oncology
Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
达拉非尼联合曲美替尼治疗黑色素瘤是需要注意哪些事项?
2025-10-19 11:44:20
Check Details
黑色素瘤服用达拉非尼和曲美替尼联合治疗效果如何?
2025-10-19 11:44:20
Check Details
达拉非尼治疗携带BRAF突变的黑色素瘤效果怎么样?
2025-10-19 11:44:20
Check Details
服用达拉非尼治疗黑色素瘤可以降低复发风险
2025-10-19 11:44:20
Check Details
索拉非尼治疗晚期黑色素瘤:II期研究分析
2025-10-19 11:44:20
Check Details
索拉非尼联合卡铂和紫杉醇I期试验
2025-10-19 11:44:20
Check Details
黑色素瘤靶向药物之达拉非尼
2025-10-19 11:44:20
Check Details
索拉非尼联合曲美替尼可作为黑色素瘤的三期治疗方案
2025-10-19 11:44:20
Check Details
MERK-2拟制剂曲美替尼联合达拉菲尼治疗黑色素瘤的临床试验1
2025-10-19 11:44:20
Check Details
达拉非尼+曲美替尼治疗BRAF V600突变晚期皮肤黑色素瘤:日本研究
2025-10-19 11:44:20
Check Details
曲美替尼+达拉非尼+伊匹单抗可能导致重度胃肠道不良事件
2025-10-19 11:44:20
Check Details
曲美替尼+达拉非尼作为西班牙转移性黑色素瘤患者慈善用药
2025-10-19 11:44:20
Check Details
1
2
...
262
263
264
265
266
267
268
...
4162
4163
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Zongertinib for HER2-Mutant NSCLC: First-Line ORR About 76%, Brain Metastases Controlled, Manage Diarrhea and Hepatotoxicity
2
Selpercatinib Traditional Approval for RET Fusion Solid Tumors: Weight-Based Adults, BSA-Based Pediatrics, Monitor Liver, BP, QT
3
Atezolizumab Plus mFOLFOX as Adjuvant Therapy for Stage III dMMR Colon Cancer: ATOMIC DFS HR 0.50
4
Tucatinib Plus Trastuzumab and Pertuzumab Maintenance in HER2-Positive Advanced Breast Cancer: HER2CLIMB-05 Median PFS 24.9 Months
5
Zenocutuzumab (Bizengri) for NRG1 Fusion Solid Tumors: HER2×HER3 Bispecific, 750mg Q2W, NSCLC/Pancreas/Cholangiocarcinoma
6
Pemigatinib for FGFR2 Cholangiocarcinoma and FGFR1 Hematologic Use: First-Line Data, 21-Day Dosing, Phosphate and Ocular Management
7
Dabrafenib (Tafinlar) Complete Guide: Indications, Dosing, Combination Therapy and Safety
8
Binimetinib plus Encorafenib for BRAF‑Mutant Melanoma
9
Adagrasib (Krazati) for KRAS G12C: NSCLC Dosing, Titration, and CRC Regulatory Update
10
Ceritinib for ALK-Positive NSCLC: Indication, Dosing, and Safety Management
11
Enzalutamide for Prostate Cancer: Managing Fatigue, Dizziness, Hypertension, and Serious Neurocardiovascular Risks
12
Tamoxifen Long-Term Safety: Vigilance for Thrombosis and Endometrial Risks